Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Severe Outcomes, Readmission, and Length of Stay Among COVID-19 Patients with Intellectual and Developmental Disabilities

Alain K. Koyama, Emilia H. Koumans, Kanta Siricar, Amy Lavery, Joy Hsu, A. Blythe Ryerson, David A. Siegel

Centers for Disease Control and Prevention, 4770 Buford Hwy, NE, Atlanta, 30341, United States

A R T I C L E   I N F O

Article history:
Received 28 October 2021
Revised 12 January 2022
Accepted 18 January 2022

Keywords:
Developmental disorder
Intellectual disability
Autism
Cerebral palsy
Down syndrome
COVID-19

A B S T R A C T

Objectives: The aim of this study was to evaluate the association between intellectual and developmental disabilities (IDDs) and severe COVID-19 outcomes, 30-day readmission, and/or increased length of stay (LOS) using a large electronic administrative database.

Methods: Patients hospitalized with COVID-19 were identified between March 2020 and June 2021 from more than 900 hospitals in the United States. IDDs included intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD), and other intellectual disabilities. Outcomes included intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, mortality, and LOS.

Results: Among 643,765 patients with COVID-19, multivariate models showed that patients with any IDD were at a significantly greater risk of at least 1 severe outcome, 30-day readmission, or longer LOS than patients without any IDD. Compared with those without any IDD, patients with Down syndrome had the greatest odds of ICU admission (odds ratio [OR] and 95% confidence interval [CI]: 1.96 [1.73-2.21]), IMV (OR: 2.37 [2.07-2.70]), and mortality (OR: 2.33 [2.00-2.73]). Patients with ASD and those with Down syndrome both had over a 40% longer mean LOS. Patients with intellectual disabilities had a 23% (12-35%) increased odds of 30-day readmission.

Conclusions: Results suggest that patients hospitalized with COVID-19 with IDD have a significantly increased risk of severe outcomes, 30-day readmission, and longer LOS.

Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Background

Intellectual and developmental disabilities (IDDs) are a broad group of conditions characterized by physical impairments and impairments in learning, language, and/or behavior that begin during the developmental period. Comorbidities, immune dysfunction, or difficulty in accessing health care may put individuals with IDD at greater risk of severe COVID-19 outcomes (Kamalakannan et al., 2021). Population-based studies have predominately evaluated mortality risk but not other outcomes including length of stay (LOS) and readmission (Clift et al., 2021; Karpur et al., 2021; Perera et al., 2020; Turk et al., 2020). We evaluated whether IDD is associated with intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), 30-day readmission, all-cause in-hospital mortality, and/or increased LOS using a large electronic administrative database.

Methods

Data were obtained from the Premier Healthcare Database Special COVID-19 Release (Premier Applied Sciences, 2020), which includes discharge data from more than 900 hospitals representing approximately 20% of annual admissions in the United States (U.S.). Patients with COVID-19 discharged from March 1, 2020, to June 30, 2021, were identified using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) discharge codes of U07.1 (from April 2020) or B97.29 (March 2020 through April 2020). Presence of ≥1 ICD-10-CM code (codes in Table 1) for intellectual disability, cerebral palsy, Down syndrome, autism spectrum disorder (ASD), and other intellectual disabilities from January 2019 through the index hospitalization was used to ascertain IDD (categories were not mutually exclusive).

Mixed-effects models accounted for clustering by hospitals. Model 1 adjusted for potential confounders including demograph-
ics, (age, sex, race/ethnicity), socioeconomic factors (insurance type, urbanicity, U.S. Census Division), and also admission month to account for temporal variations in outcomes. As adjusting for individual comorbidities may lead to collinearity, model 2 further adjusted for the Elixhauser comorbidity index, a commonly used measure of overall comorbidity burden comprising 29 conditions, which outperforms other comorbidity indices in predicting mortality (Moore et al., 2017; Sharabian et al., 2012). Models 1 and 2 compared individuals with each IDD compared to individuals without the IDD (e.g., ASD vs. no ASD), whereas model 3 excluded patients with any IDD in the reference group (e.g., ASD vs. no IDD of any type), while controlling for the same covariates in model 2. Statistical software SAS 9.4 was used for statistical analyses.

**Results**

Among the 643,765 patients with COVID-19, patients with an IDD were generally younger and more likely to be male than patients without an IDD (Table 1). Table 2 shows adjusted estimates among patients with each IDD compared with patients without an IDD. In all models, patients with an intellectual disability had a 15% to 29% significantly higher mean odds of IMV, readmission, and mortality. Patients with Down syndrome were at the greatest risk of most outcomes, including approximately a 2-fold significant increased mean odds of ICU admission, IMV, and mortality. Patients with ASD had a 21% to 40% significantly increased odds of ICU admission and IMV. In model 1, individuals with other intellectual disabilities had a 44% to 61% increased odds of ICU admission, IMV, and readmission, although ORs were attenuated slightly in models 2 and 3. All groups were at a significantly higher risk of longer LOS; in all models, patients with Down syndrome or ASD had approximately 40% longer mean LOS.

**Discussion**

Among patients hospitalized with COVID-19, results suggest an increased risk of severe COVID-19 outcomes, readmission, and longer LOS among patients with an IDD, compared with those without an IDD. Furthermore, the sample size allowed sufficient disaggregation of DDs to reveal qualitative differences in risk across conditions and outcomes. For example, although patients with Down syndrome had the highest risk of each outcome for severe COVID-19, there was no increased risk of readmission, possibly owing to survival bias as mortality risk was high. A pre-
Table 2

| Intellectual disability (n = 5,507) | Cerebral palsy (n = 2,329) | Down syndrome (n = 1,412) | Autism spectrum disorder (n = 1,525) | Other intellectual disability (n = 1,157) |
|-----------------------------------|--------------------------|-------------------------|--------------------------------------|----------------------------------------|
| **Odds ratios (95% confidence interval)** |                          |                         |                                      |                                        |
| ICU admission                      |                          |                         |                                      |                                        |
| Model 1                            | 1.12 (1.05-1.19)         | 1.29 (1.18-1.42)        | 1.97 (1.75-2.23)                     | 1.21 (1.08-1.36)                       |
| Model 2                            | 1.09 (1.02-1.16)         | 1.07 (0.98-1.18)        | 1.95 (1.73-2.20)                     | 1.21 (1.08-1.36)                       |
| Model 3                            | 1.10 (1.04-1.17)         | 1.09 (0.99-1.20)        | 1.96 (1.73-2.21)                     | 1.23 (1.09-1.39)                       |
| IMV                               |                          |                         |                                      |                                        |
| Model 1                            | 1.28 (1.19-1.38)         | 1.32 (1.18-1.47)        | 2.30 (2.02-2.62)                     | 1.36 (1.17-1.58)                       |
| Model 2                            | 1.28 (1.19-1.37)         | 1.10 (0.98-1.23)        | 2.32 (2.03-2.65)                     | 1.36 (1.17-1.58)                       |
| Model 3                            | 1.29 (1.20-1.39)         | 1.12 (1.00-1.25)        | 2.37 (2.07-2.70)                     | 1.40 (1.21-1.63)                       |
| 30-day readmission                |                          |                         |                                      |                                        |
| Model 1                            | 1.25 (1.14-1.37)         | 1.21 (1.05-1.40)        | 0.97 (0.79-1.20)                     | 1.07 (0.88-1.30)                       |
| Model 2                            | 1.23 (1.12-1.35)         | 1.02 (0.88-1.16)        | 0.97 (0.78-1.19)                     | 1.08 (0.89-1.31)                       |
| Model 3                            | 1.23 (1.12-1.35)         | 1.03 (0.89-1.18)        | 0.98 (0.79-1.21)                     | 1.09 (0.90-1.33)                       |
| Mortality                         |                          |                         |                                      |                                        |
| Model 1                            | 1.15 (1.07-1.25)         | 1.09 (0.95-1.24)        | 2.30 (1.97-2.68)                     | 1.29 (1.06-1.55)                       |
| Model 2                            | 1.16 (1.07-1.26)         | 0.90 (0.79-1.03)        | 2.31 (1.98-2.70)                     | 1.31 (1.08-1.58)                       |
| Model 3                            | 1.17 (1.06-1.26)         | 0.91 (0.80-1.04)        | 2.33 (2.00-2.72)                     | 1.33 (1.10-1.61)                       |
| Percent difference (95% confidence interval) |                          |                         |                                      |                                        |
| Length of stay                    |                          |                         |                                      |                                        |
| Model 1                            | 1.29 (1.28-1.30)         | 1.31 (1.29-1.32)        | 1.45 (1.43-1.47)                     | 1.39 (1.36-1.41)                       |
| Model 2                            | 1.28 (1.27-1.29)         | 1.19 (1.17-1.20)        | 1.44 (1.42-1.46)                     | 1.39 (1.37-1.42)                       |
| Model 3                            | 1.29 (1.28-1.30)         | 1.21 (1.19-1.22)        | 1.46 (1.44-1.49)                     | 1.42 (1.39-1.44)                       |

Results are from logistic models for dichotomous outcomes and Poisson models for length of stay.

Level of statistical significance (α = 0.05) was adjusted for multiple comparisons using the Bonferroni-Holm method.

Abbreviations: ICU = intensive care unit, IDDs = intellectual and developmental disabilities, IMV = invasive mechanical ventilation.

Bolded estimates indicate statistical significance after Bonferroni-Holm adjustment.

Model 1: Age, sex, race/ethnicity, insurance type, admission month, urbanicity, and U.S. Census Division

Model 2: Model 1 covariates and Elixhauser comorbidity index

Model 3: Same covariates as model 2, but reference group excludes patients with any IDD

Categories for intellectual and developmental disabilities are described in detail in the footnote for Table 1.

vious study in England also showed high mortality risk for patients with Down syndrome (Clift et al., 2021). Increased readmission risk and longer LOS among patients with an IDD may be attributed to immune dysfunction, behavioral challenges, and/or greater comorbidities (Abkari et al., 2021; Kamalakannan et al., 2021; Karpur et al., 2021).

Strengths of this study include the large sample from geographically diverse hospitals. Limitations include residual confounding, potential under-ascertainment of events (readmissions were only captured if they occurred in the same hospital as the index admission), and use of ICD-10-CM codes to identify IDDs. Results may not be generalizable to hospitals not reflected in this database. For example, although some evidence suggests triaging practices may decrease access to interventions for patients with IDDs and COVID-19 (Cieza et al., 2021), this study reported an increased risk of IMV, which may be due to differing practices and resource availability among included hospitals.

This study’s findings add evidence to consider individuals with IDDs as a high-risk population to prioritize for vaccines and emerging therapies. Additional studies may confirm these findings and identify mechanisms that may be driving risk.

Competing Interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Ethics Statement

This study was reviewed by the Centers for Disease Control and Prevention and was determined exempt from institutional review board oversight and informed consent per federal regulations 45 CFR §46.101(b)(4) and 45 CFR §164.506(d)(2)(ii)(B), respectively.

References

Abkari A, Fathabadi A, Razmi M, Zarifian A, Amiri M, Ghodsi A, et al. Characteristics, risk factors, and outcomes associated with readmission in COVID-19 patients: A systematic review and meta-analysis. Am J Emerg Med 2021;52:166–73.

Cieza A, Kamenov K, Al Ghaib DA, Aresu A, Chatterji S, Chavez F, et al. Disability and COVID-19: ensuring no one is left behind. Arch Public Health 2021;79(1):148.

Clift AK, Coupland CAC, Keogh RH, Hemingway H, Hippisley-Cox J. COVID-19 Mortality Risk in Down Syndrome: Results From a Cohort Study of 8 Million Adults. Ann Intern Med 2021;174(4):572–6.

Kamalakannan S, Bhattacharjya S, Bogdanova Y, Papadimitriou C, Arango-Lasprilla JC, Bentley J, et al. Health Risks and Consequences of a COVID-19 Infection for People with Disabilities: Scoping Review and Descriptive Thematic Analysis. Int J Environ Res Public Health 2021;18(8).

Karpur A, Vasudevan V, Shih A, Frazier T. Brief Report: Impact of COVID-19 in Individuals with Autism Spectrum Disorders: Analysis of a National Private Claims Insurance Database. Journal of Autism and Developmental Disorders 2021.

Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying Increased Risk of Readmission and In-hospital Mortality Using Hospital Administrative Data: The AHRQ Elixhauser Comorbidity Index. Med Care 2017;55(7):698–705.

Pereira B, Laugharie R, Henley W, Zabel A, Lamb K, Branford D, et al. COVID-19 deaths in people with intellectual disability in the UK and Ireland: descriptive study. BJPsych Open 2020;6(6):el23.

Premier Applied Sciences, Premier Healthcare Database white paper: data that informs and performs; 2020. Available from: http://offers.premierinc.com/rs/381-NBB-525/images/PHD_COVID-19_White_Paper.pdf. [Accessed July 14 2021].

Sharabani MT, Aylin F, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care 2012;50(12):1109–18.

Turk MA, Landes SD, Formica MK, Goss KD. Intellectual and Developmental Disability and COVID-19 Case-fatality Trends: TriNetX Analysis. Disability and Health Journal 2020;13(3).

Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.